Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

Innovations in the Management of Hemolytic Disease of the Fetus and Newborn: The Role of the Neonatal Fc Receptor (FcRn) Pathway

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    Hemolytic disease of the fetus and newborn (HDFN) is an alloimmune disorder between the mother and fetus, one with significant risk for dire health consequences for both. Fortunately, a better understanding of the neonatal Fc receptor (FcRn) pathway along with the emergence of an inhibitor of this pathway has brought with it an opportunity to greatly reduce the potential harm associated with HDFN. Join us as Drs. Kenneth Moise and Kara Markham discuss the pathophysiology of HDFN and present key clinical data that may change the landscape of medical intervention for HDFN.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kara B. Markham, MD
    Associate Professor
    Clinical Obstetrics & Gynecology
    University of Cincinnati
    Cincinnati, OH

    Dr. Markham has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Janssen Pharmaceuticals, Inc.
    Research: Janssen Pharmaceuticals, Inc.

    Faculty:
    Kenneth J. Moise, Jr, MD

    Professor, Department of Women's Health
    Director, Comprehensive Fetal Care Center
    Dell Medical School, University of Texas at Austin
    Austin, TX

    Dr. Moise has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: BillionToOne, Inc., Health Management Associates, Inc.
    Royalty: UpToDate, Inc.
    Research: Janssen Pharmaceuticals, Inc.

    Reviewers/Content Planners/Authors:

    • Jennifer Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Robert Schneider has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiologic processes associated with hemolytic disease of the fetus and newborn (HDFN)
    • Identify current treatment approaches for HDFN
    • Explain the role of the neonatal Fc receptor (FcRn) pathway as a therapeutic target in the management of HDFN 
    • Discuss clinical data supporting a potential role for nipocalimab in the management of HDFN
  • Target Audience

    This activity is designed to meet the educational needs of maternal-fetal medicine specialists, obstetrician-gynecologists, nurse practitioners, and physician associates.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until August 8th, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)


    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    Hemolytic disease of the fetus and newborn (HDFN) is an alloimmune disorder between the mother and fetus, one with significant risk for dire health consequences for both. Fortunately, a better understanding of the neonatal Fc receptor (FcRn) pathway along with the emergence of an inhibitor of this pathway has brought with it an opportunity to greatly reduce the potential harm associated with HDFN. Join us as Drs. Kenneth Moise and Kara Markham discuss the pathophysiology of HDFN and present key clinical data that may change the landscape of medical intervention for HDFN.

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Kara B. Markham, MD
    Associate Professor
    Clinical Obstetrics & Gynecology
    University of Cincinnati
    Cincinnati, OH

    Dr. Markham has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Janssen Pharmaceuticals, Inc.
    Research: Janssen Pharmaceuticals, Inc.

    Faculty:
    Kenneth J. Moise, Jr, MD

    Professor, Department of Women's Health
    Director, Comprehensive Fetal Care Center
    Dell Medical School, University of Texas at Austin
    Austin, TX

    Dr. Moise has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: BillionToOne, Inc., Health Management Associates, Inc.
    Royalty: UpToDate, Inc.
    Research: Janssen Pharmaceuticals, Inc.

    Reviewers/Content Planners/Authors:

    • Jennifer Brutsche has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Barry Fiedel, PhD, has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Robert Schneider has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the pathophysiologic processes associated with hemolytic disease of the fetus and newborn (HDFN)
    • Identify current treatment approaches for HDFN
    • Explain the role of the neonatal Fc receptor (FcRn) pathway as a therapeutic target in the management of HDFN 
    • Discuss clinical data supporting a potential role for nipocalimab in the management of HDFN
  • Target Audience

    This activity is designed to meet the educational needs of maternal-fetal medicine specialists, obstetrician-gynecologists, nurse practitioners, and physician associates.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until August 8th, 2025. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

  • Provider(s)/Educational Partner(s)


    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Janssen Scientific Affairs, LLC.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule6 Nov 2024